贝伐单抗治疗埃洛替尼耐药转移性脑肿瘤有助于晚期NSCLC的长期生存：一例报告

{"title":"贝伐单抗治疗埃洛替尼耐药转移性脑肿瘤有助于晚期NSCLC的长期生存：一例报告","authors":"A. Uchiyama, M. Sata, H. Yamasawa, Satoshi Arai, A. Takigami, Y. Nagai, K. Hagiwara","doi":"10.4993/acrt.30.139","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":35647,"journal":{"name":"Annals of Cancer Research and Therapy","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bevacizumab for an erlotinib-resistant metastatic brain tumor contributed to long-term survival in advanced NSCLC: A case report\",\"authors\":\"A. Uchiyama, M. Sata, H. Yamasawa, Satoshi Arai, A. Takigami, Y. Nagai, K. Hagiwara\",\"doi\":\"10.4993/acrt.30.139\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":35647,\"journal\":{\"name\":\"Annals of Cancer Research and Therapy\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-07-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Cancer Research and Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4993/acrt.30.139\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Cancer Research and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4993/acrt.30.139","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}